COVID Convalescent Plasma

BIOLOGICAL3 trials

Sponsors

Gailen D. Marshall Jr., MD PhD, Makerere University, Institute of Hematology & Blood Diseases Hospital, China

Conditions

COVID-19Covid19Hematopoietic Stem Cell Transplantation

Early Phase 1

COVID-19 Convalescent Plasma (CCP) Transfusion

CompletedNCT04412486

Gailen D. Marshall Jr., MD PhDCOVID-19

Start: 2020-06-01End: 2023-03-23Updated: 2023-11-29

Unknown Phase

Assessment of Safety and Efficacy of CCP

CompletedNCT04542941

Makerere UniversityCovid19

Start: 2020-06-16End: 2020-12-31Updated: 2021-01-15

A Study to Evaluate the Safety and Efficacy of COVID-19 Convalescent Plasma (CCP) Transfusion to Prevent COVID-19 in Adult Recipients Following Hematopoietic Stem Cell Transplantation

Institute of Hematology & Blood Diseases Hospital, ChinaCOVID-19, Hematopoietic Stem Cell Transplantation

Start: 2023-06-10End: 2025-01-01Target: 72Updated: 2023-06-15

Related Papers

Convalescent plasma therapy for COVID-19 prophylaxis in adults early post-hematopoietic stem cell transplantation: one-year outcomes from a randomized controlled trial.

2025-11-28

Efficacy of convalescent plasma for treatment of COVID-19 in Uganda

BMJ Open Respiratory Research2021-08-0136 citations